ReviewDie Ophthalmologie2026
[Clinical endpoints and translational challenges].
Review in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptogenetic vision-restorative approaches have entered the clinical stage of development.
objectiveThis article provides an overview of the current status of translation. It discusses specific aspects relating to the identification of a suitable study group and the selection of endpoints. It also focuses on patients' expectations on this novel therapy. MATERIAL AND
methodsA narrative review article is presented.
resultsClinicaltrials.gov lists eight different treatment studies pursuing the approach of optogenetic restoration of vision. The results from three of these have been published in peer-reviewed journals. Now that proof of concept has been successfully demonstrated in patients, future approaches must focus on restoring more complex visual perception in order to offer maximum added value. When identifying suitable patient groups, the status of retinal remodelling must be considered, as must the fact that patients with no remaining native visual impressions already benefit from a lower functional gain. Study endpoints should be chosen so that they specifically probe the function of the optogenetic actuator and meet the requirements of the regulatory authorities for treatment approval.
conclusionOptogenetics has reached the clinical development phase. Following proof of concept, the focus is now on further developing the approach so that it will also enable complex vision.
Indexed as
Identifiers
41667897What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.